Results of microsatellite instability/LOH analysis and MSH2, MLH1, MSH6, and β-catenin protein immunoexpression for carcinomas and adenomas from patients included in the study
| Immunoexpression | ||||||||
|---|---|---|---|---|---|---|---|---|
| Patient | No of adenomas | Analysed samples | MSI analysis | LOH analysis | MSH2 | MLH1 | MSH6 | Nuclear β-catenin |
| MSI, microsatellite instability; MSS, microsatellite stability; LOH, loss of heterozygosity; AI, allelic imbalance; D2S, D2S123; D5S, D5S346; N, normal; Y, yes (normal expression); nuclear expression of β-catenin (− absence of expression; + less than 25% expression; ++ between 25% and 50% expression; +++ more than 50% expression). | ||||||||
| 1 | 20–50 | Carc | MSS | LOH (TP53) | Y | Y | Y | ++ |
| Ad 1 (LGD) | MSS | N | Y | Y | Y | + | ||
| Ad 2 (LGD, HGD) | MSS | N | Y | Y | Y | ++ (LGD), +++ (HGD) | ||
| 2 | 29 | Carc | MSS | LOH (D2S, D5S, TP53) | Y | Y | Y | ++ |
| Ad (LGD) | MSS | LOH (D2S), AI (D5S) | Y | Y | Y | +++ | ||
| 3 | 6 | Carc | MSS | N | Y | Y | Y | + |
| Ad (HGD) | MSS | N | Y | Y | Y | +++ | ||
| 4 | 12 | Ad (LGD, HGD) | MSS | LOH (D2S), AI (D5S) | Y | Y | Y | +++ |
| Ad (LGD) | MSS | AI (D2S, D5S) | Y | Y | Y | +++ | ||
| 5 | 50 | Carc | MSS | LOH (D2S) | No | Y | No | − |
| Ad (LGD) | MSS | LOH (D2S) | Y | Y | Y | + | ||
| 6 | 20–30 | Ad 1 (LGD) | MSS | N | Y | Y | Y | ++ |
| Ad 2 (LGD) | MSS | N | Y | Y | Y | + | ||
| Ad 3 (LGD) | MSS | N | Y | Y | Y | +++ | ||
| 7 | 30 | Ad 1 (LGD) | MSS | N | Y | Y | Y | − |
| Ad 2 (LGD) | MSS | N | Y | Y | Y | +++ | ||
| 8 | 40–50 | Ad (LGD) | MSS | N | Y | Y | Y | + |
| 9 | 28 | Ad 1 (LGD) | MSS | AI (D5S) | Y | Y | Y | + |
| Ad 2 (LGD) | MSS | N | Y | Y | Y | ++ | ||
| 10 | 30 | Carc | MSS | N | Y | Y | Y | +++ |
| Ad 1 (LGD) | MSS | N | Y | Y | Y | − | ||
| Ad 2 (LGD) | MSS | N | Y | Y | Y | +++ | ||
| 11 | 40 | Carc | MSS | N | Y | Y | Y | +++ |
| Ad 1 (HGD) | MSS | N | Y | Y | Y | +++ | ||
| Ad 2 (LGD) | MSS | N | Y | Y | Y | +++ | ||
| 12 | 30 | Carc | MSS | LOH (D2S), AI (TP53) | Y | Y | Y | + |
| 13 | 8 | Carc | MSS | N | Y | Y | No | Rare |
| Ad 1 (LGD) | MSS | N | Y | Y | Y | − | ||
| Ad 2 (LGD) | MSS | N | Y | Y | Y | − | ||
| 14 | 13 | Ad (LGD) | MSS | N | Y | Y | Y | − |
| 15 | 7 | Ad 1 (LGD) | MSS | LOH (D5S), AI (D2S) | Y | Y | Y | +++ |
| Ad 2 (LGD) | MSS | AI (D5S) | Y | Y | Y | +++ | ||
| Ad 3 (LGD) | MSS | LOH (D5S) | Y | Y | Y | ++ | ||
| 16 | 9 | Ad 1 (LGD) | MSS | N | Y | Y | Y | − |